Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Savara Inc (SVRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Savara's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.6800 -0.2700    -5.45%
03:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
4.8300
+0.1500
+3.2051%
6:33:31 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,406,908
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 4.6050 - 5.0000
Savara 4.6800 -0.2700 -5.45%

Savara Inc Company Profile

 
Get an in-depth profile of Savara Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

37

Equity Type

ORD

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Contact Information

Address 1717 Langhorne Newtown Road Suite 300
Langhorne, 19047
United States
Phone (512) 614-1848
Fax -

Top Executives

Name Age Since Title
Joseph S. McCracken 71 2013 Lead Independent Director
Francesco Bonella - - Member of Clinical Advisory Board
Matthew Pauls 53 2017 Chairman & CEO
Nevan Charles Elam 57 2009 Independent Director
Richard J. Hawkins 75 2010 Independent Director
David A. Ramsay 59 2017 Independent Director
Yoshikazu Inoue - - Member of Clinical Advisory Board
Bruce C. Trapnell - - Member of Clinical Advisory Board
Tisha Wang - 2023 Member of Clinical advisory Board
Cormac McCarthy - 2021 Member of Clinical Advisory Board
An van Es-Johansson 64 2019 Independent Director
Ricky Lijing Sun 50 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SVRA Comments

Write your thoughts about Savara Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email